<DOC>
	<DOCNO>NCT00319566</DOCNO>
	<brief_summary>The purpose study determine whether hormone replacement therapy post menopausal woman coronary artery disease prevent future heart attack death coronary heart disease .</brief_summary>
	<brief_title>Heart Estrogen-Progestin Replacement Study ( HERS )</brief_title>
	<detailed_description>A randomize , blind trial post menopausal woman cornaornary artery disease test hypothesis , among 2340 woman uterus , randomized receive estrogen-progestin replacement therapy ( Premanrin .625 mg daily plus medroxygrprogesterone acetate 2.5 mg daily ) frequency new CHD event ( myocardial infarction CHD death ) randomize placebo .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>&lt; 75 y.o . uterus present postmenopausal evidence CHD sign consent MI , CABG , mechanical revascularization within 6 month serum triglyceride &gt; 300mg/dl use hormone therapy estrogen vaginal cream past 3 month history DVT pulmonary embolism history breast cancer mammogram suggestive cancer history endometrial cancer abnormal uterine bleeding pap smear abnormal SGOT 1.2 time normal Disease judge fatal within 4 yrs alcoholism , drug abuse NYHA Class IV congestive heart failure uncontrolled hypertension uncontrolled diabetes participation investigational study</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>Coronary Heart Disease</keyword>
	<keyword>Hormone replacement therapy</keyword>
	<keyword>Estrogen</keyword>
	<keyword>Postmenopausal woman</keyword>
</DOC>